
ChromaDex Corporation CDXC
Quarterly report 2025-Q3
added 11-04-2025
ChromaDex Corporation EV - Enterprise Value 2011-2025 | CDXC
Annual EV - Enterprise Value ChromaDex Corporation
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 408 M | 129 M | 123 M | 181 M | 276 M | 246 M | 171 M | 191 M | 155 M | 111 M | - | 165 M | 61.4 M | 78.3 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 408 M | 61.4 M | 177 M |
EV - Enterprise Value of other stocks in the Biotechnology industry
| Issuer | EV - Enterprise Value | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
ARCA biopharma
ABIO
|
436 M | - | 1052.0 % | $ 415 M | ||
|
AbbVie
ABBV
|
337 B | $ 223.01 | -0.99 % | $ 395 B | ||
|
Alpine Immune Sciences
ALPN
|
363 M | - | - | $ 2.17 B | ||
|
Arbutus Biopharma Corporation
ABUS
|
457 M | $ 4.68 | 1.85 % | $ 777 M | ||
|
Aclaris Therapeutics
ACRS
|
192 M | $ 3.38 | 3.21 % | $ 261 M | ||
|
AlloVir
ALVR
|
-64.1 M | - | 4.14 % | $ 49.1 M | ||
|
Acasti Pharma
ACST
|
24 M | - | 4.01 % | $ 150 M | ||
|
Adaptimmune Therapeutics plc
ADAP
|
2.15 B | - | -15.15 % | $ 60.3 M | ||
|
Ampio Pharmaceuticals
AMPE
|
-1.05 M | - | -11.43 % | $ 502 K | ||
|
Aeglea BioTherapeutics
AGLE
|
725 M | - | - | $ 1.01 B | ||
|
Ascendis Pharma A/S
ASND
|
726 M | $ 212.3 | 5.5 % | $ 5 B | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
1.95 B | - | - | $ 40.3 B | ||
|
Albireo Pharma
ALBO
|
417 M | - | -0.23 % | $ 916 M | ||
|
Ayala Pharmaceuticals
AYLA
|
5.32 M | - | - | $ 7.46 M | ||
|
Aptorum Group Limited
APM
|
9.45 M | $ 1.33 | -1.48 % | $ 7.25 M | ||
|
Alterity Therapeutics Limited
ATHE
|
-28.9 M | $ 3.4 | 1.49 % | $ 8.18 B | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
3.41 B | - | -1.52 % | $ 24.7 M | ||
|
AstraZeneca PLC
AZN
|
57.7 B | $ 90.34 | -1.28 % | $ 96.9 B | ||
|
Amphastar Pharmaceuticals
AMPH
|
2 B | $ 25.76 | 0.19 % | $ 1.25 B | ||
|
Anika Therapeutics
ANIK
|
300 M | $ 9.53 | -1.19 % | $ 140 M | ||
|
Brickell Biotech
BBI
|
515 K | - | -5.38 % | $ 6.06 M | ||
|
BeiGene, Ltd.
BGNE
|
253 B | - | 0.49 % | $ 251 B | ||
|
Biogen
BIIB
|
28.3 B | $ 173.03 | -2.55 % | $ 25.2 B | ||
|
BioVie
BIVI
|
-12.6 M | $ 1.54 | -2.53 % | $ 2.28 M | ||
|
Bellicum Pharmaceuticals
BLCM
|
-9.74 M | - | -9.72 % | $ 5.89 M | ||
|
Berkeley Lights
BLI
|
115 M | - | -7.31 % | $ 87 M | ||
|
Aytu BioScience
AYTU
|
-15.2 M | $ 2.33 | 2.3 % | $ 14.6 M | ||
|
Arena Pharmaceuticals
ARNA
|
5.65 B | - | -6.81 % | $ 3.04 B | ||
|
Baudax Bio
BXRX
|
29.8 M | - | 0.59 % | $ 63 K | ||
|
Avenue Therapeutics
ATXI
|
-1.23 M | - | -52.27 % | $ 4.45 M | ||
|
Catalyst Biosciences
CBIO
|
38.1 M | $ 15.32 | 5.73 % | $ 1.01 B | ||
|
Институт стволовых клеток человека
ISKJ
|
14.1 M | - | - | - | ||
|
Axon Enterprise
AXON
|
41.5 B | $ 586.28 | 3.15 % | $ 44.4 B | ||
|
Cerus Corporation
CERS
|
425 M | $ 2.14 | 13.23 % | $ 395 M | ||
|
Checkpoint Therapeutics
CKPT
|
174 M | - | - | $ 169 M | ||
|
Caladrius Biosciences
CLBS
|
-6.94 M | - | -16.75 % | $ 25.8 M | ||
|
Celldex Therapeutics
CLDX
|
18.3 M | $ 28.33 | 0.5 % | $ 1.82 M | ||
|
Cellectar Biosciences
CLRB
|
60.8 M | $ 3.81 | -5.35 % | $ 46.6 M | ||
|
Clovis Oncology
CLVS
|
839 M | - | -7.23 % | $ 13 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
647 M | $ 0.29 | -5.01 % | $ 631 M | ||
|
Cortexyme
CRTX
|
132 M | - | -1.05 % | $ 67.1 M | ||
|
Benitec Biopharma
BNTC
|
461 M | $ 12.91 | 0.78 % | $ 531 M | ||
|
Cytokinetics, Incorporated
CYTK
|
1.45 B | $ 60.38 | 0.11 % | $ 6.76 M | ||
|
BioNTech SE
BNTX
|
-6.64 B | $ 95.9 | 0.17 % | $ 27.2 B | ||
|
Deciphera Pharmaceuticals
DCPH
|
1.24 B | - | - | $ 2.18 B | ||
|
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
10.2 B | $ 11.55 | 8.86 % | $ 747 M | ||
|
Dynavax Technologies Corporation
DVAX
|
2.02 B | $ 10.89 | -0.09 % | $ 1.42 B | ||
|
Eloxx Pharmaceuticals
ELOX
|
18.7 M | - | -5.68 % | $ 8.28 M | ||
|
Acer Therapeutics
ACER
|
38.2 M | - | 2.71 % | $ 14 M |